Hopp til hovedinnhold
Toggle navigation
Live markets
Search
Search
Search
Search
My profile
My Subscriptions
Watchlists
Quote alerts
Create account
Sign in
NB
FR
EN
PT
NL
NB
DE
IT
Hjem
Company Press Releases
Company press releases
Abonner
Filtre
Filtre
Oppdater
Nullstill
Icon After
Dato
Toggle Visibility
Alle
I dag
Denne uken
Denne måneden
Tilpasset datosøk
Fra
Til
Kategori
Toggle Visibility
Alliances and agreements
Annen informasjonspliktig regulatorisk informasjon
Change in Capital
Commercial operations
Commercial results
Corporate life
Dividend
Eks.dato
Endringer i rettighetene til aksjer / verdipapirer
Flagging
General meeting / Board Meeting
Halvårsrapporter og revisjonsberetninger / uttalelser om forenklet revisorkontroll
Ikke-informasjonspliktige pressemeldinger
Income
Innsideinformasjon
Joint venture
Journal / appointments
Kapital- og stemmerettsendringer
Legal
Meetings / events
Meldepliktig handel for primærinnsidere
Mergers, Acquiqitions, Transferts
New
New establishment
News contracts
Other financial transaction
Other subject
Polls / Surveys
Products and services
Prospekt / opptaksdokument
Rapportering om betaling til myndigheter (land-for-land rapportering)
Rating
Renteregulering
Sales
Share history
Share introduction and issues
Takeover bids
Trends / Analyses
Utsteders meldeplikt ved handel i egne aksjer
Valg av hjemstat
Årsrapporter og revisjonsberetninger
Leverandør
Toggle Visibility
ActusNewsWire
BusinessWire
EQS Group
Euronext
GlobeNewswire
Les Echos
Marketwire
Modular Finance
Oslo Børs Newspoint
PR Newswire
Viser 101 - 150 av 171 resultater
Tid
Selskap
Tittel
Sektor
Kategori
12 Feb 2022
20:49 CET
AB SCIENCE
AB Science - Clarification following the February 11, 2022 public hearing of the Enforcement Committee of the French Market Regulator (AMF)
20103010 Biotechnology
New
12 Feb 2022
20:49 CET
AB SCIENCE
AB Science - Mise au point suite à la séance publique du 11 février 2022 de la Commission des sanctions de l’Autorité des Marchés Financiers (AMF)
20103010 Biotechnology
New
07 Feb 2022
18:12 CET
AB SCIENCE
AB Science to present on its Amyotrophic Lateral Sclerosis (ALS) development program at the 2022 ALS Drug Development Summit
20103010 Biotechnology
New
07 Feb 2022
18:12 CET
AB SCIENCE
AB Science présentera son programme de développement dans la Sclérose Latérale Amyotrophique (SLA) lors de l’édition 2022 du ALS Drug Development Summit
20103010 Biotechnology
New
02 Feb 2022
18:12 CET
AB SCIENCE
AB Science a reçu l’autorisation de l’Agence de Santé Suédoise pour initier une étude confirmatoire de Phase III avec le masitinib dans les formes progressives de la sclérose en plaques
20103010 Biotechnology
New
02 Feb 2022
18:12 CET
AB SCIENCE
AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the Swedish Medical Products Agency
20103010 Biotechnology
New
19 Jan 2022
18:02 CET
AB SCIENCE
AB Science a reçu l’autorisation de l’ANSM pour initier une étude de Phase II chez les patients atteints du syndrome d’activation des mastocytes sévère
20103010 Biotechnology
New
19 Jan 2022
18:02 CET
AB SCIENCE
AB Science has been granted authorization to initiate Phase II study in patients with severe mast cell activation syndrome by the French Health Authority (ANSM)
20103010 Biotechnology
New
03 Jan 2022
18:10 CET
AB SCIENCE
AB Science a reçu l’autorisation de l’ANSM pour initier une étude confirmatoire de Phase III avec le masitinib dans les formes progressives de la sclérose en plaques
20103010 Biotechnology
New
03 Jan 2022
18:10 CET
AB SCIENCE
AB Science granted authorization to initiate confirmatory Phase III trial of masitinib in progressive forms of multiple sclerosis by the French Health Authority (ANSM)
20103010 Biotechnology
New
29 Nov 2021
20:57 CET
AB SCIENCE
AB Science annonce le recrutement du premier patient dans l'étude de phase 2 évaluant l'activité antivirale du masitinib contre le virus SARS-CoV-2 (COVID-19)
20103010 Biotechnology
New
29 Nov 2021
20:57 CET
AB SCIENCE
AB Science announces dosing of first patient in Phase 2 trial of masitinib’s antiviral activity against the SARS-CoV-2 (COVID-19) virus
20103010 Biotechnology
New
22 Nov 2021
18:20 CET
AB SCIENCE
AB Science received FDA authorization to initiate Phase 1/II trial of AB8939 in the treatment of acute myeloid leukemia
20103010 Biotechnology
New
22 Nov 2021
18:20 CET
AB SCIENCE
AB Science reçoit l'approbation de la FDA pour initier une étude de phase I/II avec la molécule AB8939 dans le traitement de la leucémie myéloïde aiguë
20103010 Biotechnology
New
18 Nov 2021
20:40 CET
AB SCIENCE
AB Science received authorization from the FDA to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in patients with ALS
20103010 Biotechnology
New
18 Nov 2021
20:40 CET
AB SCIENCE
AB Science reçoit l’autorisation de la FDA de reprendre le recrutement des patients dans l'étude confirmatoire de phase 3 du masitinib (AB19001) chez les patients atteints de SLA
20103010 Biotechnology
New
18 Oct 2021
18:14 CEST
AB SCIENCE
AB Science granted authorization from the French Health Authority (ANSM) to initiate a study of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
20103010 Biotechnology
New
18 Oct 2021
18:14 CEST
AB SCIENCE
AB Science obtient l’autorisation de l’ANSM d’initier une étude avec la molécule AB8939 dans le traitement de la leucémie myéloïde aigue (LMA)
20103010 Biotechnology
New
04 Oct 2021
18:10 CEST
AB SCIENCE
AB Science receives FDA authorization to start clinical development program of masitinib in mast cell activation syndrome (MCAS)
20103010 Biotechnology
New
04 Oct 2021
18:10 CEST
AB SCIENCE
AB Science reçoit l’autorisation de la FDA pour initier le programme de développement clinique du masitinib dans le syndrome d’activation des mastocytes (MCAS)
20103010 Biotechnology
New
30 Sep 2021
19:21 CEST
AB SCIENCE
AB Science annonce aujourd’hui ses résultats financiers semestriels au 30 juin 2021 et présente un point sur ses activités
20103010 Biotechnology
Income
30 Sep 2021
19:21 CEST
AB SCIENCE
AB Science today reports its revenues for the first half of 2021 and provides an update on its activities
20103010 Biotechnology
Income
28 Sep 2021
19:25 CEST
AB SCIENCE
AB Science a reçu l’autorisation d’initier une seconde étude de Phase 2 dans le traitement de la Covid-19
20103010 Biotechnology
New
28 Sep 2021
19:25 CEST
AB SCIENCE
AB Science receives regulatory authorization to commence a second Phase 2 Covid-19 study
20103010 Biotechnology
New
22 Sep 2021
18:09 CEST
AB SCIENCE
AB Science a reçu l’approbation de l’autorité de santé canadienne pour initier une étude de Phase I/II avec sa molécule AB8939 dans le traitement de la leucémie myéloïde aiguë (LMA)
20103010 Biotechnology
New
22 Sep 2021
18:09 CEST
AB SCIENCE
AB Science receives Health Canada approval letter to commence Phase I/II trial of AB8939 in the treatment of Acute Myeloid Leukemia (AML)
20103010 Biotechnology
New
20 Sep 2021
19:15 CEST
AB SCIENCE
AB Science annonce aujourd'hui qu'un résumé des résultats de survie à long terme du masitinib dans SLA a été sélectionné pour une présentation lors de la réunion annuelle de la Société Espagnole de Neurologie
20103010 Biotechnology
New
20 Sep 2021
19:15 CEST
AB SCIENCE
AB Science announced that an abstract on the long-term survival of masitinib in ALS has been selected for a platform presentation at the Annual Meeting of the Spanish Society of Neurology
20103010 Biotechnology
New
16 Sep 2021
19:34 CEST
AB SCIENCE
AB Science announced today that it has received authorization to resume patient enrollment in the phase 2 masitinib study of COVID-19 (AB20001)
20103010 Biotechnology
New
16 Sep 2021
19:34 CEST
AB SCIENCE
AB Science annonce aujourd'hui avoir reçu l'autorisation de reprise des inclusions de patients dans l'étude de phase 2 du masitinib dans la COVID-19 (AB20001)
20103010 Biotechnology
New
14 Sep 2021
18:01 CEST
AB SCIENCE
AB Science announced that it has received new authorizations to resume patient enrollment in its Phase 3 studies of masitinib
20103010 Biotechnology
New
14 Sep 2021
18:01 CEST
AB SCIENCE
AB Science annonce avoir reçu de nouvelles autorisations portant sur la reprise des inclusions de ses études de phase 3 du masitinib
20103010 Biotechnology
New
13 Sep 2021
18:04 CEST
AB SCIENCE
AB Science announced today that results from masitinib study AB12003 in prostate cancer have been presented at the 2021 American Urological Association
20103010 Biotechnology
New
13 Sep 2021
18:04 CEST
AB SCIENCE
AB Science annonce que les résultats de l'étude AB12003 du masitinib dans le cancer de la prostate ont été présentés lors du congrès annuel 2021 de l'American Urological Association
20103010 Biotechnology
New
02 Sep 2021
17:59 CEST
AB SCIENCE
AB Science announced today that latest clinical data on long-term survival analyses in ALS will be presented at the 2021 symposium on ALS/MND
20103010 Biotechnology
New
02 Sep 2021
17:59 CEST
AB SCIENCE
AB Science annonce aujourd’hui que les dernières données cliniques de survie à long terme dans la SLA seront présentées au colloque international 2021 de la SLA et des maladies du motoneurone
20103010 Biotechnology
New
25 Aug 2021
18:46 CEST
AB SCIENCE
AB Science annonce avoir reçu une seconde autorisation, portant sur la reprise des inclusions dans l'étude de phase 3 du masitinib dans la mastocytose
20103010 Biotechnology
New
25 Aug 2021
18:46 CEST
AB SCIENCE
AB Science announces that it has received a second authorization to resume patient enrollment, in the Phase 3 study of masitinib in mastocytosis
20103010 Biotechnology
New
23 Aug 2021
19:43 CEST
AB SCIENCE
AB Science annonce avoir reçu la première autorisation de de reprise des inclusions dans l’étude de phase 3 confirmatoire du masitinib (AB19001) dans la SLA
20103010 Biotechnology
New
23 Aug 2021
19:43 CEST
AB SCIENCE
AB Science announces that it has received the first authorization to resume patient enrollment in the confirmatory Phase 3 study of masitinib (AB19001) in ALS
20103010 Biotechnology
New
19 Aug 2021
17:51 CEST
AB SCIENCE
AB Science annonce la publication d'un mécanisme pathogène déclenché par les mastocytes dans la moelle épinière de la sclérose latérale amyotrophique (SLA) qui peut être ciblé par le masitinib
20103010 Biotechnology
New
19 Aug 2021
17:51 CEST
AB SCIENCE
AB Science announced the publication of a pathogenic mechanism triggered by mast cells in the amyotrophic lateral sclerosis (ALS) spinal cord that can be targeted by masitinib
20103010 Biotechnology
New
06 Aug 2021
19:02 CEST
AB SCIENCE
AB Science diffuse un communiqué de Questions - Réponses faisant suite à son communiqué du 28 juin dernier relatif à la signature d’un accord avec des actionnaires historiques
20103010 Biotechnology
Alliances and agreements
06 Aug 2021
19:02 CEST
AB SCIENCE
AB Science publishes a Q&A press release, following-up on its June 28, 2021 press release relating to an agreement with historical shareholders
20103010 Biotechnology
Alliances and agreements
29 Jul 2021
18:06 CEST
AB SCIENCE
AB Science announced that results from its Phase 3 AB09004 study on mild to moderate Alzheimer’s disease have been presented at the AAIC
20103010 Biotechnology
New
29 Jul 2021
18:06 CEST
AB SCIENCE
AB Science annonce que les résultats de son étude de phase 3 dans la maladie d’Alzheimer ont été présentés à la AAIC
20103010 Biotechnology
New
22 Jul 2021
18:10 CEST
AB SCIENCE
AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)
20103010 Biotechnology
New
22 Jul 2021
18:10 CEST
AB SCIENCE
AB Science annonce qu’un résumé de son étude de phase 3 dans la maladie d’Alzheimer a été sélectionné pour une présentation orale à la Alzheimer’s Association International Conference (AAIC)
20103010 Biotechnology
New
20 Jul 2021
18:08 CEST
AB SCIENCE
AB Science announces the publication of an article in the world-renowned journal Science that confirms potential of masitinib as a treatment of Covid-19 with anti-viral activity against SARS-CoV-2 and all tested variants of concern
20103010 Biotechnology
New
20 Jul 2021
18:08 CEST
AB SCIENCE
AB Science annonce la publication d’un article dans la revue de renommée mondiale Science qui confirme le potentiel du masitinib comme traitement de la Covid-19 avec une activité antivirale contre le SARS-CoV-2 et tous ses variants testés
20103010 Biotechnology
New
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Press release
Open in new window
Sider
«
« First
‹
‹‹
2
3
4
›
››
»
Last »
Company press releases subscription
×
To subscribe to Press releases from this issuer, visit the Subscription to Company news section in
Hjem
Markeder
Amsterdam
Cash Products
Aksjer
AEX index Stocks
AEX ESG Stocks
Indekser
Fond
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksopsjoner
Indeksfutures
Aksjeopsjoner
Utbyttederivater
Aksjefutures
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Brussel
Cash products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
Expert Market
BEL 20 Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Expert Market
Dublin
Stocks
Euronext regulated
Euronext Growth
ISEQ 20 Stocks
Indices
Funds
Bonds
Irish Government Bonds
DOL
Lisboa
Cash Products
Aksjer
Euronext regulated
Euronext Access
PSI Stocks
Indekser
Obligasjoner
Derivater
Indeksfutures
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Milan
Cash Products
Stocks
Euronext Milan
Euronext Growth Milan
Euronext Star Milan
Euronext Global Equity Market
EuroTLX
Trading After Hours
MIB ESG Stocks
Bonds
MOT
Euronext Access Milan
EuroTLX
Structured Products
SeDeX
EuroTLX
ETFs
Funds
Derivative products
All derivatives
Index futures
Index options
Stock options
Stock futures
Dividend derivatives
Quote Vendor Codes
IPOs
Oslo
Aksjer, renter, indekser
Aksjer
Oslo Børs
Euronext Growth
Euronext Expand
Top performers
OBX aksjer
OBX ESG aksjer
OSEBX aksjer
OSEFX Aksjer
Seafood Aksjer
Shipping Aksjer
Aksjeindekser
Obligasjoner
Oslo Børs
Nordic Alternative Bond Market
Obligasjonsindekser
ETFer
Fond
Derivater
Derivative products
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Finanskalender
Primærinnsidere
Paris
Cash Products
Aksjer
Euronext regulated
Euronext Growth
Euronext Access
CAC 40 Stocks
CAC 40 ESG Stocks
Indekser
Obligasjoner
ETF-er
Strukturerte produkter
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
Quote Vendor Codes
Selskapsmeldinger
Latest
Archive
Aksjer
All Markets directories
All Markets
Euronext regulated
Euronext Growth
Euronext Access
Euronext Expand
Euronext Global Equity Market
EuroTLX
Trading After Hours
Selskapsmeldinger
Latest
Archive
Nye aksjenoteringer
Alle aksjenoteringer
Euronext Growth advisors
Euronext Tech Leaders
Family business
Indekser
Directory
Grønne indekser
Indices documents
Indices news
Indekser høringer
Kontakter Euronext-indekser
ETF-er
Directory
Grønne ETF-er
Fond
Directory
ESG Funds
Oslo Mutual Funds
Obligasjoner
Grønne obligasjoner
1.5° Bonds
All Markets directories
All Markets
Amsterdam
Brussels
Dublin
Lisbon
Oslo
Milan
Paris
Strukturerte produkter
Directory / search
Bid-Only trading status
Trading Turbos in the Netherlands
Derivater
Indeksfutures
Indeksopsjoner
Aksjeopsjoner
Aksjefutures
Utbyttederivater
ETF opsjoner
Kontraktsspesifikasjoner
Tick sizes
Rapportering av handler
Leverandørkoder markedsdata
Råvarer
Quotes
Quotes snapshot
Milling Wheat futures
Rapeseed futures
Corn futures
European Durum Wheat Futures
Milling Wheat options
Rapeseed options
Corn options
Bortfallskalendre
Bortfall
Wholesale Trading
Commitments of Traders (CoT) report
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Knowledge Centre
Bid & Ask
Options Investing E-learning
Contract Specifications
Position Management
Intrinsic Value
Premium & Valuation
Moneyness
Positions
Euronext News
Ressurser
Statistikk & rapporter
Quality of execution
Åpningstider
Kontraktsspesifikasjoner
Leverandørkoder markedsdata
Key Information Document
Class level
Product group level
Notices / Corporate actions
Cash Notices / Corporate actions
Derivatives corporate actions
All Corporate Actions
Latest
Unusual Contract Sizes, Dividends
Corporate Action Services
Corporate Action Policies
Derivatives notices
Markedshendelser
Suspenderte instrumenter
Stressed Market Conditions
Brudd på Double Cap limits
Ekstraordinære markedsforhold
Diverse meldinger
Market status
Medlemsliste
Issuers compliance
Hvor du finner hva